These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9667952

  • 1. Assessment of the radiochemical design of antibodies with a metabolizable linkage for target-selective radioactivity delivery.
    Arano Y, Wakisaka K, Akizawa H, Ono M, Kawai K, Nakayama M, Sakahara H, Konishi J, Saji H.
    Bioconjug Chem; 1998; 9(4):497-506. PubMed ID: 9667952
    [Abstract] [Full Text] [Related]

  • 2. Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications.
    Arano Y, Wakisaka K, Ohmono Y, Uezono T, Akizawa H, Nakayama M, Sakahara H, Tanaka C, Konishi J, Yokoyama A.
    Bioconjug Chem; 1996; 7(6):628-37. PubMed ID: 8950481
    [Abstract] [Full Text] [Related]

  • 3. A novel radioiodination reagent for protein radiopharmaceuticals with L-lysine as a plasma-stable metabolizable linkage to liberate m-iodohippuric acid after lysosomal proteolysis.
    Wakisaka K, Arano Y, Uezono T, Akizawa H, Ono M, Kawai K, Ohomomo Y, Nakayama M, Saji H.
    J Med Chem; 1997 Aug 01; 40(16):2643-52. PubMed ID: 9258371
    [Abstract] [Full Text] [Related]

  • 4. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels.
    Arano Y, Fujioka Y, Akizawa H, Ono M, Uehara T, Wakisaka K, Nakayama M, Sakahara H, Konishi J, Saji H.
    Cancer Res; 1999 Jan 01; 59(1):128-34. PubMed ID: 9892197
    [Abstract] [Full Text] [Related]

  • 5. Stability of a metabolizable ester bond in radioimmunoconjugates.
    Arano Y, Wakisaka K, Mukai T, Uezono T, Motonari H, Akizawa H, Kairiyama C, Ohmomo Y, Tanaka C, Ishiyama M, Sakahara H, Konishi J, Yokoyama A.
    Nucl Med Biol; 1996 Feb 01; 23(2):129-36. PubMed ID: 8868284
    [Abstract] [Full Text] [Related]

  • 6. Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides.
    Xu LC, Nakayama M, Harada K, Kuniyasu A, Nakayama H, Tomiguchi S, Kojima A, Takahashi M, Ono M, Arano Y, Saji H, Yao Z, Sakahara H, Konishi J, Imagawa Y.
    Bioconjug Chem; 1999 Feb 01; 10(1):9-17. PubMed ID: 9893958
    [Abstract] [Full Text] [Related]

  • 7. Maleimidoethyl 3-(tri-n-butylstannyl)hippurate: a useful radioiodination reagent for protein radiopharmaceuticals to enhance target selective radioactivity localization.
    Arano Y, Wakisaka K, Ohmomo Y, Uezono T, Mukai T, Motonari H, Shiono H, Sakahara H, Konishi J, Tanaka C.
    J Med Chem; 1994 Aug 05; 37(16):2609-18. PubMed ID: 8057303
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice.
    Koizumi M, Endo K, Watanabe Y, Saga T, Sakahara H, Konishi J, Yamamuro T, Toyama S.
    Cancer Res; 1989 Apr 01; 49(7):1752-7. PubMed ID: 2924318
    [Abstract] [Full Text] [Related]

  • 9. A newly designed radioimmunoconjugate releasing a hippurate-like radiometal chelate for enhanced target/non-target radioactivity.
    Arano Y, Matsushima H, Tagawa M, Inoue T, Koizumi M, Hosono M, Sakahara H, Endo K, Konishi J, Yokoyama A.
    Nucl Med Biol; 1994 Jan 01; 21(1):63-9. PubMed ID: 9234265
    [Abstract] [Full Text] [Related]

  • 10. Relationship between in vitro binding activity and in vivo tumor accumulation of radiolabeled monoclonal antibodies.
    Sakahara H, Endo K, Koizumi M, Nakashima T, Kunimatsu M, Watanabe Y, Kawamura Y, Nakamura T, Tanaka H, Kotoura Y.
    J Nucl Med; 1988 Feb 01; 29(2):235-40. PubMed ID: 3162255
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels.
    Uehara T, Koike M, Nakata H, Hanaoka H, Iida Y, Hashimoto K, Akizawa H, Endo K, Arano Y.
    Bioconjug Chem; 2007 Feb 01; 18(1):190-8. PubMed ID: 17226973
    [Abstract] [Full Text] [Related]

  • 12. In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels.
    Fujioka Y, Satake S, Uehara T, Mukai T, Akizawa H, Ogawa K, Saji H, Endo K, Arano Y.
    Bioconjug Chem; 2005 Feb 01; 16(6):1610-6. PubMed ID: 16287261
    [Abstract] [Full Text] [Related]

  • 13. Renal brush border enzyme-cleavable linkages for low renal radioactivity levels of radiolabeled antibody fragments.
    Akizawa H, Imajima M, Hanaoka H, Uehara T, Satake S, Arano Y.
    Bioconjug Chem; 2013 Feb 20; 24(2):291-9. PubMed ID: 23330714
    [Abstract] [Full Text] [Related]

  • 14. Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates.
    Quadri SM, Vriesendorp HM.
    Q J Nucl Med; 1998 Dec 20; 42(4):250-61. PubMed ID: 9973840
    [Abstract] [Full Text] [Related]

  • 15. Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments.
    Fujioka Y, Arano Y, Ono M, Uehara T, Ogawa K, Namba S, Saga T, Nakamoto Y, Mukai T, Konishi J, Saji H.
    Bioconjug Chem; 2001 Dec 20; 12(2):178-85. PubMed ID: 11312678
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H, Wu C, Kim MK, Paik CH, Carrasquillo JA, Brechbiel MW.
    Bioconjug Chem; 1999 Dec 20; 10(1):103-11. PubMed ID: 9893971
    [Abstract] [Full Text] [Related]

  • 17. Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.
    Shin IS, Jang BS, Danthi SN, Xie J, Yu S, Le N, Maeng JS, Hwang IS, Li KC, Carrasquillo JA, Paik CH.
    Bioconjug Chem; 2007 Dec 20; 18(3):821-8. PubMed ID: 17375899
    [Abstract] [Full Text] [Related]

  • 18. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
    Safavy A, Khazaeli MB, Safavy K, Mayo MS, Buchsbaum DJ.
    Clin Cancer Res; 1999 Oct 20; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
    [Abstract] [Full Text] [Related]

  • 19. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb 20; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 20. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.
    Cancer Res; 1997 Jan 01; 57(1):100-5. PubMed ID: 8988048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.